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Humanized mouse models have become increasingly important and widely used in modeling human
diseases in biomedical research. Immunodeficient mice such as NOD-Rag1-/-IL2RgammaC-null (NRG) or
NOD-SCID-IL2RgammaC-null (NSG) mice are critical for efficient engraftment of human cells or tissues.
However, their genetic modification remains challenging due to a lack of embryonic stem cells and difficulty
in the collection of timed embryos after superovulation. Here, we report the generation of gene knockout
NRG mice by combining in vitro fertilization (IVF) and CRISPR/Cas9 technology. Sufficient numbers of
fertilized embryos were produced through IVF, and a high rate of Fah gene targeting was achieved with
microinjection of Cas9 mRNA, gRNA and single strand oligonucleotide DNA (ssDNA) into the embryos.
The technology paves the way to construct NRG or NSG mutant mice to facilitate new humanized mouse
models. The technology can also be readily adapted to introduce mutations in other species such as swine
and non-human primates.
S
mall animal models are valuable tools to decipher the mechanism of gene function, disease and to test new
therapeutics in vivo. However, translation of these studies to the clinic has met with limited success due to
the species-specific differences between rodents and humans. Non-human primates serve as the best
alternative to model human disease. Nevertheless, the prohibitively high cost and ethical concerns have limited
their wide use. Recently, the ban on use of chimpanzees in biomedical research in Europe and the United States
National Institutes of Health highlights the urgent need of in vivo models with the closest relevance to human,
such as immunodeficient mice engrafted with human cells, tissues and organs. Immunodeficient mice with no T,
B and NK cells are permissive as recipients for human cell engraftment and have been widely employed in
investigation of human diseases including human-specific infections (as reviewed in1,2) such as virus infection
(HIV, EBV, Dengue Virus, HBV, HCV), bacterial infection, protozoan infection; and in regenerative medicine,
such as allograft (skin, liver, islet)3, organ regeneration4,5, and drug evaluation6.
Among the available models, immunodeficient mice with the NOD genetic background, such as NRG and
NSG, have shown the highest permissiveness for human cell engraftment7. One major determinant of NOD mice
is the unique cross-reactive activity of the NOD SIRP-a with its human receptor CD47, which reduces human
rejection by NOD macrophages8. However, the limited availability of embryonic stem (ES) cells from immuno-
deficient and NOD mice9–13 and the difficulty of isolating embryos by natural mating14 have prohibited direct
genetic manipulation to construct new NOD mutant models. As a result, all current knockout or transgenic NOD
mice have been created by back crossing mutant mice from other genetic backgrounds, which is a time consuming
(about 2 years) and labor intensive process. Although humanized mice with human blood and immune cells have
been significantly improved in recent years, additional humanization in other organs such as liver remains
challenging15,16.
Fumarylacetoacetate hydrolase (Fah) encodes the last enzyme in the tyrosine catabolism pathway, and Fah
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the Fah mutant mouse liver in the FRG (Fah-/-Rag2-/-IL2g-/-)
mouse18,19, which have been used to model human metabolism, liver
injury, gene regulation, drug toxicity, and hepatotropic infections
(reviewed in20). However, the role of the human immune system in
these processes cannot be investigated because the current FRG mice
in the C57/B6 background only poorly support the engraftment of
human hematopoietic stem cells. More importantly, the mouse Sirpa
gene is genetically linked with the Rag1 and Rag2 genes, making it
extremely difficult to derive NRG-Fah mutant mice with the NOD
Sirpa allele by genetic crossing. The ability to introduce additional
mutations directly in embryos from NRG or NSG mice would greatly
facilitate further improvements in humanized mouse models.
Novel approaches, such as zinc finger nuclease (ZFN), transcrip-
tion activator-like effector nucleases (TALENs), and CRISPR/Cas9
nucleases, have greatly accelerated the production of genetically
modified mice using direct injection of DNA or mRNA into one-cell
stage embryos21–25, allowing construction of knockout mice by
directly manipulating a small number of embryos.
Here, we report a strategy to directly inactivate the Fah gene in
NRG mice by combining IVF and CRISPR/Cas technologies. With
IVF, sufficient numbers of fertilized embryos were obtained for
microinjecting gRNA, Cas9 mRNA and single strand DNA
(ssDNA). A high success rate (.80%) of allele modifications was
detected in the offspring, and the modified alleles were germline
transmissible. Germline transmissible NRG-Fah mutant mice were
generated in only 16 weeks. We have thus established a protocol to
rapidly introduce genetic mutations directly in NRG mice, which can
also be adapted to other mouse strains and other species.
Results
Generation of gRNAs targeting the mouse Fah gene. The murine
Fah gene has 14 exons and encodes a 419 amino acid hydrolase
responsible for the degradation of fumarylacetoacetic acid to fumarate
and acetoacetate in the last step of the tyrosine catabolism pathway. To
introduce a null mutation in the Fah gene in the NRG background,
exon 5 was chosen as previously reported26. Three gRNAs targeting the
exon 5 splice donor sequence and coding region were selected (Fig. 1a).
Two complementary oligo DNAs were annealed and inserted into BsaI
linearized vectors pT7-BsaI-gRNA-Kan. The gRNAs were generated in
vitro with T7 RNA polymerase using the linearized DNA as template.
The function of each guide RNA was tested in vitro by mixing the
gRNA, Cas9 protein and a PCR segment (650 bp) covering the three
gRNA target sites. As illustrated in Fig. 1b, all three gRNAs can direct
Cas9 cleavage of their target sites in vitro. The cutting efficiency was
analyzed using a DNA TapeStation (Fig. 1c). No cleavage was observed
when only Cas9 was added. However, DNA cleavage was observed
when each gRNA was added, indicating all three gRNAs were
functional. The cutting efficiencies of gRNA1, 2 and 3 are 54.26%,
23.15% and 42.05%, respectively.
Production of NRG embryos using in vitro fertilization and genetic
manipulation by pronuclear microinjection. It is challenging to get
fertilized eggs or embryos from NRG mice through natural mating.
Experienced NRG stud males failed to plug NRG females that had
been superovulated using a standard PMSG/HCG hormone regimen
(data not shown). The failure to copulate was confirmed by the
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Figure 1 | gRNAs targeting Fah exon5 can efficiently direct Cas9 cleavage of target DNA. (a) gRNA sequences against Fah exon5. The exon 3, 4, 5 and 6
region of the mouse Fah gene is shown. The exon5 sequence (upper case) and part of the upstream intron sequence (lower case) are shown with 3 gRNA
sequences (labeled in red), and the PAM sequence NGGs in turquoise. (b) and (c) gRNA cleavage efficiency in vitro. (b) Schematic diagram of gRNA
mediated Cas9 DNA cleavage. The PCR DNA product containing the gRNA target sites, Cas9 nuclease protein and gRNA are mixed. The Cas9/gRNA
complex cuts the PCR product into two fragments. (c) The cleaved DNA was resolved on TapeStation. A0(L), DNA ladder; A1, PCR DNA alone; B1, PCR
DNA 1 Cas9 nuclease; C1, D1 and E1, PCR DNA 1 Cas9 nuclease 1 gRNA1 (C1), gRNA2 (D1) and gRNA 3 (E1). Full-length gel is shown. The gRNA
mediated cutting efficiency is shown below each lane.
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females, although oocyte numbers were indicative of successful
superovulation. Failure of obtaining fertilized embryos by natural
mating was also reported in the NOD-SCID mouse14. To
overcome the lack of plugging and fertilization by NRG males, we
used IVF to produce embryos from NRG mice (Fig. 2a). IVF is a
widely used assisted reproductive technology, and has been shown to
be highly effective to produce healthy mice27. Male NRG mice were
individually caged for 10 days before sperm isolation. Female NRG
mice were dosed with 5 IU PMSG, followed 48 hours later by 5 IU of
HCG. Oocytes were isolated 14 h after HCG injection, were mixed
with capacitated sperm and incubated in vitro for 6 h. Oocytes
isolated from females from 4–10 weeks old could be efficiently
fertilized in vitro (Table 1). However, fewer oocytes were obtained
from 4 week old mice than 6–10 wk old animals. After identifying
the fertilized embryos, the gRNA, Cas9 mRNA and ssDNA were
delivered to the pronucleus of fertilized embryos still in one cell
stage by microinjection using a continuous flow injection mode.
Surviving embryos were subsequently implanted into the oviducts
of pseudo-pregnant Swiss Webster recipient females. The resulting
offspring were screened for mutated Fah alleles.
Fig. 2b illustrates the Fah gene editing procedures. Cas9 nuclease is
translated from injected mRNA using the cell translation machinery.
The Cas9/gRNA complex finds and cleaves the gRNA target site,
creating a DNA double strand break (DSB). DSBs can be repaired
by cellular repair mechanisms including error-prone non-homolog-
ous end joining (not shown) and homologous recombination (HR).
The introduced ssDNA with homology to the sequences flanking the
Cas9/gRNA target site can be used as a template for HR-mediated
repair, and has been demonstrated to be a better alternative to the
traditional longer targeting vectors in mediating the homologous
recombination22,28. The ssDNA contains two successive in-frame
stop codons and a BamHI site (not shown). After homologous
recombination the stop codons and BamHI site will be incorporated
into the genomic DNA, generating a truncated FAH as reported26.
Identification of NRG mice with the genetically edited Fah alleles.
We tested Fah mutagenesis using both Cas9 wild type (WT) nuclease
and the Cas9 nickase mutant (D10A)29 (Table 2). The Cas9 (WT)
nuclease can utilize a single gRNA to mediate site-specific DSBs,
which can be repaired through either non-homologous end joining
(NHEJ) or homology-directed repair (HDR). The Cas9 (D10A)
mutant is a nickase version of Cas9 that can only cause a DSB
when provided with two gRNAs targeting sites near each other on
opposite strands. These DSBs can be repaired through NHEJ or
HDR, while any off-target cleavage activity by Cas9 (D10A) results
in single strand nicks that are typically repaired through high-fidelity
HDR, resulting in lower risk of germline transmissible off-target
mutagenesis29,30. In the first injection session, gRNA3 and Cas9
(WT) mRNA were injected, and 201 injected embryos were
transferred into 8 pseudopregnant surrogate females. 4 females
gave birth to a total of 11 pups (including 2 dead pups). In the
second injection, gRNA1, gRNA3 and Cas9 (D10A) mRNA were
injected, and 147 embryos were transferred into 6 pseudopregnant
recipient females. 2 females gave birth to 11 pups (including 1 pup
that died and was not recovered for genotyping). Genomic DNA was
extracted for PCR amplification and the purified PCR products were
then subjected to BamHI digestion (Fig. 3a). Of the 9 pups (#1-1 to
#1-10) from the first microinjection, 5 had insertion of the BamHI
site, including homozygous insertion in mouse #1-8. From the
second injection, none of the 10 pups had BamHI site insertion.
However, 3 mice from injection 2 showed evidence of large
biallelic deletions at the Fah locus. Mouse #2-7 gave an amplicon
approximately 250 bp shorter than expected, and no amplicon was
obtained from mouse #2-3 and #2-9, even when the PCR amplicon
was extended to cover 400 bp each side from the cutting sites (data
not shown). Together, these data indicate that both Cas9 (WT) and
Cas9 (D10A) gave efficient editing at the Fah locus in NRG embryos.
To define the mutations in the Fah gene, the PCR products were
subjected to DNA sequencing. The two alleles of each mouse were
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Figure 2 | Strategy to generate NRG Fah knockout mice. (a) Schematic illustration of IVF and pronuclear microinjection. Female NRG mice are
superovulated with PMSG and hCG followed by oocyte collection. Sperm is collected from male NRG mice. The oocytes and sperm are incubated to
generate fertilized eggs and embryos, which are then microinjected with gRNA, Cas9 mRNA and ssDNA in the pronucleus. The injected embryos are then
transferred into pseudopregnant surrogate mothers. Mouse pups are genotyped. (b) Mechanism of gRNA, Cas9 mRNA, and ssDNA mediated Fah gene
knockout. Cas9 mRNA is translated into Cas9 protein after microinjection. The Cas9/gRNA complex binds the genomic DNA and generates DSBs. The
ssDNA contains homologous sequence spanning the double strand break sites with ,50 bp on each side, two stop codons and a BamHI site. The ssDNA
can be used as a template for homologous recombination to introduce the stop codons and BamHI site. The mouse is drawn by the authors (F.L. and L.S.),
using Adobe Photoshop and Adobe Illustrator.
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labeled with A and B (Fig. 3b). One allele of mouse #1-1 had the
knock-in stop codons and BamHI site, while the other allele had a
17 bp deletion. One allele of mouse #1-2 and #1-10 had the knock-in
stop codons and BamHI site, while the other was wild type. Mouse
#1-3 had 3 alleles detectable by sequencing: one was the knock-in
stop codons and BamHI site, another was a 102 bp deletion, and the
third was wild type. The BamHI digestion for this animal also showed
an additional band under the wild type product, which was presum-
ably the band with the 102 bp deletion (Fig. 3a). The PCR digestion
and sequence results confirmed that mouse #1-3 was a mosaic
mouse. Both alleles of mouse #1-8 had the knock-in sequence.
Although mice #1-4, #1-5, #1-6, and #1-7 didn’t have the knock-in
sequence, they had indels (insertion and/or deletion mutations),
indicating their genomic DNA had been cut by Cas9. One allele of
mouse #1-4 had a 1 bp deletion, and the other allele had a 5 bp
insertion. One allele of mouse #1-5 had a 5 bp deletion, and the other
allele was wild type. One allele of mouse #1-6 had a 5 bp deletion, and
the other allele was a replacement of 7 bp with a 12 bp insertion.
Both alleles of mouse #1-7 had a 4 bp deletion. Sequence results
confirmed that mouse #2-7 had a 246 bp deletion spanning exon5
and its upstream intron. The alleles of mice #2-1, #2-2, #2-4, #2-5, #2-
6, #2-9, #2-10 from the second injection were wild type without any
modification.
Successful germline transmission of the knockout Fah allele.
Founder mouse #1-1 was chosen to breed with male NRG mice to
test whether the edited Fah allele is germline transmittable. A specific
primer (FAH-Probe) targeting the edited sequence introduced by
ssDNA was used to amplify the knockout allele. As shown in
Fig. 4a, the primers FAH-F1 and FAH-R1 can amplify 560 or
565 bp segments using the wild type and knockout alleles as
templates, respectively, but the FAH-F1 and FAH-Probe can only
amplify the knockout allele to generate a short amplicon (454 bp).
Mouse #1-1 had normal litter size with typical Mendelian inheritance
(Fig. 4b). Of the 10 pups, 2 females and 2 males had the Fah knockout
allele, and 3 females and 3 males had only the wild type allele. This
result demonstrates that the Fah knockout alleles generated in NRG
mice are germline transmissible.
Discussion
Both NRG and NSG mice are widely used for engrafting human
normal and tumor cells (reviewed in ref. 1,31), since they can support
efficient engraftment of human hematopoietic stem cells and human
immune system maturation7,8. However, significant barriers have
impeded the introduction of additional genetic modifications in
NRG and NSG mice. The difficulty of deriving germline-competent
ES cell lines from NOD strains, including NRG and NSG, has hin-
dered efforts to perform gene targeting in these strains. Although
more robust protocols have recently been developed for ES cell
derivation from NOD or other ‘‘non-permissive’’ strains11–13, such
ES cells are not widely available and their utility for gene targeting
and germline transmission remain to be fully established. Transgenic
manipulation of NRG and NSG mice through embryo microinjec-
tion is also difficult due to the poor embryo yields produced through
natural mating14,32. Thus, nearly all current NOD transgenic and
NOD knockout mice were derived by backcrossing the mutant genes
or transgenes from other mouse strains. To our knowledge, our work
represents the first report of the successful generation of genetically
modified mutant mice in NOD-derived immunodeficient mice using
RNA-guided Cas9 nucleases and IVF. The manipulation of mam-
malian genomes has been significantly facilitated by the recent
development of novel approaches to target DNA breaks to specific
loci using nucleases such as ZFNs, TALENs and CRISPR21–25. The
easy design and high targeting efficiency of CRISPR/Cas9 technology
enables the fast generation of knock-in and knockout mice by
directly manipulating a small number of embryos using microinjec-
tion25. To overcome previous limitations of the NRG strain, IVF was
conducted and combined with the CRISPR/Cas9 gene editing tech-
nology. The relatively low number of embryos required for successful
gene modification by microinjection was easily obtained using our
IVF approach (Table 2). The CRISPR/Cas9 technology gave efficient
genetic modification in NRG embryos, enabling production of a
novel mutant strain in the NRG background in a few weeks. This
approach has several advantages compared to ES cell approaches,
including shorter timelines, reduced costs and higher probability of
germline transmission.
Fah knockout mice in other mouse backgrounds can support
robust human hepatocyte repopulation in the chimeric liver, which
have been successfully used to model human metabolism, liver injury,
gene regulation, drug toxicity, and human hepatotropic infec-
tions18–20. Crossing the Fah mutation to NRG or NSG background
would require at least 2 years (10 backcrosses, and 1 intercross,
10 week/cross cycle), which is a time consuming and labor intensive
procedure. More importantly, since the NOD Sirp-a gene is genetic-
ally linked with Rag1/2 on chromosome 2, generation of NOD-Fah-/-
Rag2-/-IL2rg-/- mice by backcrossing Fah-/-Rag2-/-IL2rg-/- mice
with NOD mice would require a rare meiotic crossover event to
combine the NOD Sirpa and Rag mutant alleles. The animals
obtained after 10 backcross generations would therefore be unlikely
to have the NOD Sirpa allele33, resulting in continued poor human
cell repopulation activity. Our system avoids this issue by generating
the Fah mutant allele directly in the NSG background.
In our experiments, Cas9 (WT) was much more efficient than
Cas9 (D10A) at inducing mutations in the Fah gene. The Cas9
(WT) protein creates a double strand break (DSB) at the gRNA
target site, but may have a risk of off-target mutagenesis. The Cas9
D10A mutant, on the other hand, is converted to a nickase, and only
makes nicks on one strand of the target DNA, limiting DSBs to sites
with adjacent gRNA targets on opposite strands. While the nickase
strategy is a promising way to reduce the risk of off-target activity, it
Table 1 | Summary of in vitro fertilization (IVF)
Mouse age (weeks) 4 6 8 10
Female Number 3 9 6 7
Total oocytes 62 487 394 507
Fertilized embryos 45 173 160 156
Fertilization rate (%) 72.6 35.5 40.6 30.8
Embryos/mouse 15 19.2 26.7 22.3
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**201 injected embryos were transferred. One recipient received 11 injected and 10 non-injected embryos. This recipient did not produce any births.
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was much less efficient than Cas9 (WT) in our experiments (100%
mutation efficiency with Cas9 (WT) vs 30% with Cas9 (D10A)).
Moreover, we did not obtain any mice with homologous insertion
of the oligonucleotide donor using the Cas9 nickase approach, while
over 50% of mice obtained from the Cas9 (WT) injections had the
knock-in event. This suggests that the nickase approach will require
additional development to define conditions for efficient induction
of homologous recombination in mouse embryos.
In summary, we have established a technology to derive embryos
by IVF combined with a highly effective CRISPR/Cas9-based system
to produce targeted mutations in immunodeficient NRG mice.
Importantly, the same procedures can be readily applied to edit the
genomes of other mammals such as swine and non-human primates.
Methods
Ethics statement. All animal experiments were conducted following NIH guidelines
for housing and care of laboratory animals and in accordance with the University of
North Carolina at Chapel Hill in accordance with protocols approved by the
institution’s Institutional Animal Care and Use Committee (protocol numbers 13-
088 and 12-250).
Plasmid construction. The gRNAs were identified using the online software (http://
www.genome-engineering.org/crispr/?page_id541). Complementary oligos for each
target sequence were heated at 95uC for 5 mins, and annealed by decreasing 0.20uC/
second to 16uC using a PCR machine (BioRad). Then, the short double strand DNA
fragment were ligated into BsaI linearized pT7-BsaI-gRNA-Kan. Primers for each
target RNA are as follows: gRNA1 (59- TATAGTCCGTGTAGTCTCCTGCAG-39,
59-AAACCTGCAGGAGACTACACGGAC-39), gRNA2(59- TATAGCACGGAC-
TTCTACTCTTCT-39, 59-AAACAGAAGAGTAGAAGTCCGTGC-39), and gRNA3
(59- TATAGGGCAGCATGCCACCAATGT-39, 59-AAACACATTGGTGGCATG-
CTGCCC-39). Plasmids were prepared using MiniPrep kit (Qiagen) and MidiPrep kit
(Qiagen). The sequence was confirmed by sequencing (Eton Bioscience Inc.).
mRNA and gRNA preparation. gRNAs were generated through in vitro
transcription reaction using T7 High Yield RNA Synthesis Kit (NEB #E2040S).
Briefly, 1 mg DraI linearized template DNA was used in a 20 ml reaction following kit
guidelines for short RNA transcripts. The reaction was incubated at 37uC overnight,
followed by DNase I (RNase-free) digestion for 15 mins at 37uC. The gRNAs were
then purified using an RNEasy Column following guidelines for short RNA
purification (Qiagen).
Capped and polyadenylated Cas9 and Cas9-D10A mRNAs were prepared through
in vitro transcription reaction using mMESSAGE mMACHINE T7 ULTRA KIT (Life
Technologies AM1345). Briefly, to generate Capped mRNA. 1 mg hCas9-T7 or
hCas9-D10A-T7 linearized plasmid DNA was added into a 20 ml reaction containing
13 NTP/ARCA, 13 T7Reaction Buffer, and 2 ml T7 Enzyme. The reaction was
incubated at 37uC for 1 h, followed by addition of 1 ml TURBO DNase and digestion
at 37uC for 15 mins. To add polyA tails to the Capped mRNA, the 20 ml reaction mix
from step1 was mixed with Nuclease-free Water (36 ml), 53 E-PAP Buffer (20 ml),
25 mM MnCl2 (10 ml), ATP Solution (10 ml), and E-PAP (4 ml) to a final reaction
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Figure 3 | Genotyping and sequence analysis of founder mice. (a) PCR results of founder mice. Mice from two microinjection sessions were genotyped by
PCR amplification and BamHI digestion. PCR and BamHI digestion products were electrophoresed in 1.2% argorose gel. Mice from the first injection
session (wild type Cas9 mRNA) were labeled #1-1 to #1-10, and mice from the second injection session (mutant D10A Cas9 mRNA) were labeled #2-1 to
#2-10. Wild type mouse genomic DNA was used as negative control (WT con). Cropped gels are shown. Full-length gels are provided for review in the
supplementary file. (b) Sequence analysis of the mutated Fah alleles. The wild type sequence of exon5 is shown on top, with the encoded amino acids
indicated above the sequence. The gRNA targeting sites are shown in red letters and PAM NGGs in turquoise. The mutant alleles of each mouse are labeled
with A and B, following the mouse ID number. The indels for each mutated allele from different mice are shown in the middle. The deleted sequences are
marked in gray, and the inserted sequences are shown below the wild type sequence. The deletion or insertion length of each indel is shown on the right. The
Fah mutant alleles with the knock-in sequence are shown in the lower panel. Only one sequence is shown for the stop codon (@) and BamHI insertion. Indel,
insertion and deletion; in, insertion; del, deletion.
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volume of 100 ml. The reaction was incubated at 37uC for 30–45 mins. The capped &
polyadenylated RNA was purified by LiCl precipitation and resuspended in micro-
injection buffer (5 mM Tris, 0.1 mM EDTA, pH 7.5).
Mouse genomic DNA extraction and PCR. The mouse gDNA was extracted from
mouse toe or ear samples using the KAPA Mouse Genotyping Kit. Briefly, tissues
around 2 mm3 were digestion in a 100 ml volume containing 88 ml PCR-grade H2O,
2 ml 103 KAPA express Extract buffer and 2 ml KAPA Express Extract Enzyme, at
75uC for 15 mins, followed by 95uC for 5 mins to inactivate the enzyme. Primers used
for the PCR are as follows: FAH-F1, (59-AATGGGAGAAATGAGGCTAAGGAGC-
39, FAH-R1 (59-AGGGTCTTTGCTGCTGGGAAAAA-39), FAH-R2(59-
TCATGCTGAGGGAACCAAAAGCC-39), FAH-Probe(59-
TGAACATAATGCCAACATGATCATCC-39).
In vitro guide RNA test. His-tagged Cas9 protein was expressed in bacteria and
purified using Ni-NTA agarose and gel exclusion chromatography (Protein
Expression and Purification Core Facility, UNC Chapel Hill). 1 mg of a PCR segment
(650 bp) covering the gRNA target site, 600 ng of gRNA obtained by in vitro
transcription and 0.6 mg CAS9 protein were mixed in a 20 ml reaction with 13 NEB
buffer 3 and 53 BSA (NEB). The reaction was incubated at 37uC for 1 h, followed by
heat inactivation of Cas9 by adding loading dye and incubating at 80uC 10 mins.
The cut DNA was electrophoresed in a TapeStation (Agilent), and the cutting
efficiency was calculated by the following formula, cutting efficiency (%) 5 sum (cut
large band 1 cut small band)/sum (uncut PCR DNA 1 cut large band 1 cut small
band) 3 100.
Superovulation and In Vitro fertilization (IVF). Female NRG mice (4–10 weeks of
age) were superovulated by intraperitoneal injection with 5 IU pregnant mare serum
gonadotropin (National Hormone & Peptide Program, NIDDK), followed 48 hours
later by injection of 5 IU human chorionic gonadotropin (hCG, National Hormone &
Peptide Program, NIDDK). The animals were sacrificed 14 hours following hCG
administration and oviducts collected. Oocyte-cumulus complexes were released
from the oviducts and placed in pre-equilibrated fertilization drops consisting of
Cook’s Media (Cook Medical Research).
Fresh sperm was isolated from the epididymis and vas deferens of male NRG mice
(5 months of age) into Cook’s medium under mineral oil. Sperm capacitation was
performed by incubation (37uC, 5% O2, 5% CO2, 90% N2) in Cook’s medium for 1
hour.
Fertilization was carried out in Cook’s medium under mineral oil by transferring
oocyte-cumulus complexes to fertilization drops containing the activated sperm and
incubating for 6 hours (37uC, 5% O2, 5% CO2, 90% N2). After incubation, the oocytes
were washed in fresh Cook’s medium to remove excess sperm, transferred to Cook’s
medium and incubated until microinjection performed.
Pronuclear microinjection and transfer to pseudopregnant recipients. Fertilized
embryos with visible pronuclei following IVF were selected for pronuclear
microinjection and transferred to microinjection dishes containing M2 medium
under mineral oil. The CRISPR/Cas reagent mixture was prepared by dilution of the
components into injection buffer (5 mM Tris, 0.1 mM EDTA, pH 7.5) to obtain the
following concentrations: 100 ng/ml Cas9 mRNA (wild-type or D10A), 50 ng/ml FAH
guide RNA, 100 ng/ml single stranded donor oligonucleotide (59- GGGTGTTCC-
CTCTGCAGGAGACTACACGGACTTCTACTCTTCTTGATAGGATCCTAGG-
ATGATCATGTTGGCATTATGTTCAGAGGCAAGGAGAATGCGCTGTTG-
CCA-39). The reagent mixture was introduced into the pronuclei of fertilized
embryos by microinjection using a continuous flow injection mode. Surviving
embryos were surgically implanted into the oviducts of pseudopregnant Swiss
Webster recipient females. The resulting offspring were analyzed for editing of the
Fah gene.
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